ImageneBio (IMA) Net Margin (2020 - 2025)

ImageneBio (IMA) posted Net Margin of 1141.0% for Q1 2025, down 546.09% sequentially from 176.6% in Q3 2024.

ImageneBio (IMA) Net Margin (2020 - 2025) Analysis & Trends

ImageneBio has reported Net Margin for 6 years, with the latest figure at 1141.0% in Q1 2025.

Quarterly Net Margin changed N/A year-over-year to 1141.0% in Q1 2025, while the trailing twelve-month figure through Mar 2025 was 804.44% (changed N/A YoY) and the FY2023 annual result came in at 744.17%, down 30370.0% from the prior year.
Net Margin eased to 1141.0% in Q1 2025 per IMA's latest filing, from 176.6% in the prior quarter.
Over five years, Net Margin peaked at 150.75% in Q4 2021 and troughed at 561240.05% in Q2 2022.
A 5-year average of 42284.22% and a median of 1229.63% in 2021 frame the typical range for Net Margin.
The sharpest annual moves came in 2022 and 2023: Net Margin tumbled 55971427 bps in 2022, then jumped 56038601 bps in 2023.
Over 5 years, Net Margin stood at 150.75% in 2021, then slumped by 93 bps to 291.03% in 2022, then sank by 925 bps to 2981.94% in 2023, then jumped by 94 bps to 176.6% in 2024, then plunged by 546 bps to 1141.0% in 2025.
According to Business Quant data, Net Margin over the past three periods registered 1141.0%, 176.6%, and 2981.94% for Q1 2025, Q3 2024, and Q4 2023 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	32.99%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	30.23%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	31.16%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-539.31%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	13.90%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	12.74%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-3.12%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	12.09%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-16.51%
10	ImageneBio	48.60 Mn	-86.75 Mn	-	-

Download Data